HC Wainwright Issues Negative Outlook for TSE:FRX Earnings

Fennec Pharmaceuticals Inc. (TSE:FRX) – HC Wainwright lowered their Q3 2026 earnings estimates for Fennec Pharmaceuticals in a note issued to investors on Monday, March 30th. HC Wainwright analyst R. Selvaraju now forecasts that the biopharmaceutical company will post earnings per share of $0.17 for the quarter, down from their prior estimate of $0.26. The consensus estimate for Fennec Pharmaceuticals’ current full-year earnings is $0.60 per share. HC Wainwright also issued estimates for Fennec Pharmaceuticals’ Q4 2026 earnings at $0.22 EPS, Q3 2027 earnings at $0.36 EPS, Q4 2027 earnings at $0.42 EPS and FY2027 earnings at $1.33 EPS.

Separately, B. Riley Financial raised shares of Fennec Pharmaceuticals to a “strong-buy” rating in a research report on Wednesday, February 11th. One equities research analyst has rated the stock with a Strong Buy rating, According to data from MarketBeat.com, Fennec Pharmaceuticals presently has a consensus rating of “Strong Buy”.

Fennec Pharmaceuticals Price Performance

FRX stock opened at C$8.89 on Tuesday. The company has a market cap of C$306.48 million, a price-to-earnings ratio of -26.15 and a beta of 3.01. The company has a fifty day moving average price of C$10.50 and a 200 day moving average price of C$11.09. Fennec Pharmaceuticals has a 12 month low of C$7.02 and a 12 month high of C$13.83.

Insider Buying and Selling

In other Fennec Pharmaceuticals news, Director Rostislav Christov Raykov sold 10,349 shares of the stock in a transaction that occurred on Monday, February 2nd. The stock was sold at an average price of C$10.69, for a total transaction of C$110,630.81. Following the completion of the sale, the director directly owned 2,709,294 shares of the company’s stock, valued at approximately C$28,962,352.86. This trade represents a 0.38% decrease in their position. 16.20% of the stock is currently owned by corporate insiders.

Fennec Pharmaceuticals News Roundup

Here are the key news stories impacting Fennec Pharmaceuticals this week:

• Positive Sentiment: HC Wainwright issued a bullish FY2027 outlook, forecasting $1.33 EPS for FY2027 and stronger quarterly earnings in 2027 (Q3/Q4 2027), implying substantial revenue/profit ramp by that year — this longer‑term upgrade can support upside expectations. HC Wainwright FY2027 estimates
• Neutral Sentiment: Fennec announced inducement stock option grants (377,500 ISOs) under Nasdaq Listing Rule 5635(c)(4); this aligns management/staff incentives but adds potential dilution that investors may want to quantify. Inducement grants announcement
• Negative Sentiment: HC Wainwright cut multiple near‑term estimates for 2026 (Q1 2026 to ($0.03) from $0.10; Q2 2026 to $0.07 from $0.19; Q3/Q4 2026 also trimmed and FY2026 cut from $0.88 to $0.43), signaling weaker near‑term profitability than previously modeled — a material revision that could pressure short‑term sentiment. HC Wainwright near-term cuts

Fennec Pharmaceuticals Company Profile

Fennec Pharmaceuticals Inc is a clinical-stage biotechnology company. It is primarily engaged in research and development activities. The company is developing Sodium Thiosulfate (STS), a chemo-protectant against hearing loss associated with platinum-based chemotherapy. Its lead product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin induced hearing loss, or ototoxicity in children.